Literature DB >> 15832089

HHV-8-associated T-cell lymphoma in a lymph node with concurrent peritoneal effusion in an HIV-positive man.

Sarah E Coupland1, Frederic Charlotte, George Mansour, Karim Maloum, Michael Hummel, Harald Stein.   

Abstract

Primary effusion lymphoma (PEL) is an uncommon large cell lymphoma, usually seen in human immunodeficiency virus (HIV)-infected patients. PEL is characterized by various clinical, histomorphologic, and immunophenotypical features, and is associated with the human herpes virus 8 (HHV-8). PEL may present as either a body cavity-based lymphomatous effusion or a solid tumor mass. Most so-called "solid PEL" usually have an extranodal location; exceptionally rarely, they occur in lymph nodes. The majority of PEL consist of malignant cells of B-cell genotype; seldom they are of T-cell origin. We report a rare case of HHV-8-associated "solid PEL" of T-cell type in a 41-year-old HIV-seropositive man with a concomitant peritoneal effusion. The T-cell lymphoma was diagnosed on the basis of morphologic, immunophenotypic, and molecular findings of a lymph node biopsy. The tumor cells strongly expressed CD45R0, CD7, CD43, MUM1/IRF4, CD30, HHV-8, and EBER, and demonstrated a clonal rearrangement of T-cell receptor-gamma chain gene. The following case provides another example of a lymph node-based "solid" PEL, demonstrating the variety within the spectrum of HHV-8-associated lymphoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832089     DOI: 10.1097/01.pas.0000157937.01624.1d

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  15 in total

Review 1.  Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines.

Authors:  Antonino Carbone; Ethel Cesarman; Annunziata Gloghini; Hans G Drexler
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

2.  Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells.

Authors:  Jinjong Myoung; Don Ganem
Journal:  Virology       Date:  2011-02-25       Impact factor: 3.616

Review 3.  Primary lymphocyte infection models for KSHV and its putative tumorigenesis mechanisms in B cell lymphomas.

Authors:  Sangmin Kang; Jinjong Myoung
Journal:  J Microbiol       Date:  2017-04-29       Impact factor: 3.422

4.  HHV-8-positive and EBV-positive intravascular lymphoma: an unusual presentation of extracavitary primary effusion lymphoma.

Authors:  Genevieve M Crane; Richard F Ambinder; Courtney M Shirley; Elliot K Fishman; Yvette L Kasamon; Janis M Taube; Michael J Borowitz; Amy S Duffield
Journal:  Am J Surg Pathol       Date:  2014-03       Impact factor: 6.394

Review 5.  HIV infection and lymphoma.

Authors:  K L Grogg; R F Miller; A Dogan
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

Review 6.  Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders.

Authors:  M-Q Du; C M Bacon; P G Isaacson
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

7.  HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report-Part 3.

Authors:  Amy Chadburn; Jonathan Said; Dita Gratzinger; John K C Chan; Daphne de Jong; Elaine S Jaffe; Yasodha Natkunam; John R Goodlad
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

Review 8.  KSHV/HHV8-mediated hematologic diseases.

Authors:  Ethel Cesarman; Amy Chadburn; Paul G Rubinstein
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

9.  Macaque homologs of EBV and KSHV show uniquely different associations with simian AIDS-related lymphomas.

Authors:  A Gregory Bruce; Helle Bielefeldt-Ohmann; Serge Barcy; Angela M Bakke; Patrick Lewis; Che-Chung Tsai; Robert D Murnane; Timothy M Rose
Journal:  PLoS Pathog       Date:  2012-10-04       Impact factor: 6.823

10.  Primary effusion lymphoma involving three body cavities.

Authors:  Fadi Brimo; Gizelle Popradi; René P Michel; Manon Auger
Journal:  Cytojournal       Date:  2009-10-09       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.